Some additional highlights from the report include:
Data Source: EvaluatePharma and Individual Drug Prescribing Information
|Rank||Biologic||Expression System||Company||Rank Overall||Approved Indication|
|1||Humira (adalimumab)||CHO||AbbVie||1||Moderate to severe rheumatoid arthritis, moderate to severe chronic plaque psoriasis, moderate to severe Crohn’s disease; moderate to severe ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, moderate to severe polyarticular juvenile idiopathic arthritis|
|2||Opdivo (nivolumab)||not listed||Bristol- Myers Squibb and Ono||3||Indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.|
|3||Enbrel (etanercept)||CHO||Amgen and Pfizer||6||Moderate to severe plaque psoriasis, psoriatic arthritis, and moderate to severe rheumatoid arthritis|
|4||Remicade (infliximab)||Murine Myeloma||Johnson & Johnson and Merck & Co.||8||Moderately to severely active rheumatoid arthritis in adults, in combination with methotrexate; Crohn’s Disease in children 6 years and older, and adults who have not responded well to other medicines; rheumatoid arthritis; ankylosing spondylitis; psoriatic arthritis; chronic, severe, extensive, and/or disabling plaque psoriasis in adults; moderately to severely active ulcerative colitis in children 6 years and older and adults that have not responded well to other medicines|
|5||Avastin (bevacizumab)||CHO||Roche||9||Metastatic colorectal cancer (colon cancer), non–small cell lung cancer, glioblastoma & metastatic kidney|
|6||Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine)||Pfizer||10||Prevention of diseases caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in children ages six weeks through 17 years; prevention of otitis media caused by strains 4, 6B, 9V, 14, 18C, 19F, and 23F in children six weeks through five years; prevention of pneumococcal pneumonia and invasive disease caused by the 13 vaccine strains in adults ages 50 and older|
|7||Eylea (aflibercept)||CHO||Regeneron||11||Wet Age-related Macular Degeneration, Macular Edema following Retinal Vein Occlusion, Diabetic Macular Edema and Diabetic Retinopathy.|
|8||Soliris (eculizumab)||Murine Myeloma||Alexion Pharmaceuticals||14||Atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria.|
|9||Herceptin (trastuzumab)||CHO||Roche||15||HER2-positive breast cancer and HER2-positive metastatic gastric cancer|
|10||Rituxan||CHO||Roche and Biogen Idec||17||Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis|
- Novartis is ranked as the number one pharmaceutical company in 2014 based on highest worldwide prescription drug sales and is forecast to hold that position in 2020.
- AbbVie’s Humira is forecast to continue to account for 25% of the anti-rheumatic market in 2020 and be the top selling drug overall.
- Gilead is forecast to dominate the anti-viral market in 2020 with 50% of the market.
- The industry’s overall R&D pipeline is currently valued at $493 billion.
- Gilead’s potential new combination hepatitis C product is forecast as the most valuable product currently in the R&D pipeline.